Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 105


Effect of alteplase on the CT hyperdense artery sign and outcome after ischemic stroke.

Mair G, von Kummer R, Morris Z, von Heijne A, Bradey N, Cala L, Peeters A, Farrall AJ, Adami A, Potter G, Cohen G, Sandercock PA, Lindley RI, Wardlaw JM; IST-3 Collaborative Group.

Neurology. 2016 Jan 12;86(2):118-25. doi: 10.1212/WNL.0000000000002236. Epub 2015 Dec 9.


The Clots in Legs Or sTockings after Stroke (CLOTS) 3 trial: a randomised controlled trial to determine whether or not intermittent pneumatic compression reduces the risk of post-stroke deep vein thrombosis and to estimate its cost-effectiveness.

Dennis M, Sandercock P, Graham C, Forbes J; CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Smith J.

Health Technol Assess. 2015 Sep;19(76):1-90. doi: 10.3310/hta19760.


Exploring threats to generalisability in a large international rehabilitation trial (AVERT).

Bernhardt J, Raffelt A, Churilov L, Lindley RI, Speare S, Ancliffe J, Katijjahbe MA, Hameed S, Lennon S, McRae A, Tan D, Quiney J, Williamson HC, Collier J, Dewey HM, Donnan GA, Langhorne P, Thrift AG; AVERT Trialists’ Collaboration.

BMJ Open. 2015 Aug 17;5(8):e008378. doi: 10.1136/bmjopen-2015-008378.


Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial.

AVERT Trial Collaboration group, Bernhardt J, Langhorne P, Lindley RI, Thrift AG, Ellery F, Collier J, Churilov L, Moodie M, Dewey H, Donnan G.

Lancet. 2015 Jul 4;386(9988):46-55. doi: 10.1016/S0140-6736(15)60690-0. Epub 2015 Apr 16. Erratum in: Lancet. 2015 Jul 4;386(9988):30.


Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial.

ENOS Trial Investigators, Bath PM, Woodhouse L, Scutt P, Krishnan K, Wardlaw JM, Bereczki D, Sprigg N, Berge E, Beridze M, Caso V, Chen C, Christensen H, Collins R, El Etribi A, Laska AC, Lees KR, Ozturk S, Phillips S, Pocock S, de Silva HA, Szatmari S, Utton S.

Lancet. 2015 Feb 14;385(9968):617-28. doi: 10.1016/S0140-6736(14)61121-1. Epub 2014 Oct 21. Erratum in: Lancet. 2015 Feb 14;385(9968):606.


Effect of intermittent pneumatic compression on disability, living circumstances, quality of life, and hospital costs after stroke: secondary analyses from CLOTS 3, a randomised trial.

CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration.

Lancet Neurol. 2014 Dec;13(12):1186-92. doi: 10.1016/S1474-4422(14)70258-3. Epub 2014 Oct 31.


Tunable porous organic crystals: structural scope and adsorption properties of nanoporous steroidal ureas.

Natarajan R, Bridgland L, Sirikulkajorn A, Lee JH, Haddow MF, Magro G, Ali B, Narayanan S, Strickland P, Charmant JP, Orpen AG, McKeown NB, Bezzu CG, Davis AP.

J Am Chem Soc. 2013 Nov 13;135(45):16912-25. doi: 10.1021/ja405701u. Epub 2013 Nov 5.


Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial.

CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, Reid J, Graham C, Forbes J, Murray G.

Lancet. 2013 Aug 10;382(9891):516-24. doi: 10.1016/S0140-6736(13)61050-8. Epub 2013 May 31. Erratum in: Lancet. 2013 Aug 10;382(9891):506. Lancet. 2013 Sep 21;382(9897):1020.


Interplay of bite angle and cone angle effects. A comparison between o-C6H4(CH2PR2)(PR'2) and o-C6H4(CH2PR2)(CH2PR'2) as ligands for Pd-catalysed ethene hydromethoxycarbonylation.

Fanjul T, Eastham G, Floure J, Forrest SJ, Haddow MF, Hamilton A, Pringle PG, Orpen AG, Waugh M.

Dalton Trans. 2013 Jan 7;42(1):100-15. doi: 10.1039/c2dt31913f.


Expansion of the Ligand Knowledge Base for Chelating P,P-Donor Ligands (LKB-PP).

Jover J, Fey N, Harvey JN, Lloyd-Jones GC, Orpen AG, Owen-Smith GJ, Murray P, Hose DR, Osborne R, Purdie M.

Organometallics. 2012 Aug 13;31(15):5302-5306. Epub 2012 Jul 30.


The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

IST-3 collaborative group, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A.

Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Erratum in: Lancet. 2012 Aug 25;380(9843):730.


Vorapaxar in the secondary prevention of atherothrombotic events.

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy SA; TRA 2P–TIMI 50 Steering Committee and Investigators.

N Engl J Med. 2012 Apr 12;366(15):1404-13. doi: 10.1056/NEJMoa1200933. Epub 2012 Mar 24.


Update on the third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke and baseline features of the 3035 patients recruited.

Sandercock P, Lindley R, Wardlaw J, Dennis M, Innes K, Cohen G, Whiteley W, Perry D, Soosay V, Buchanan D, Venables G, Czlonkowska A, Kobayashi A, Berge E, Slot KB, Murray V, Peeters A, Hankey GJ, Matz K, Brainin M, Ricci S, Cantisani TA, Gubitz G, Phillips SJ, Antonio A, Correia M, Lyrer P, Kane I, Lundstrom E; IST-3 collaborative group.

Trials. 2011 Nov 30;12:252. doi: 10.1186/1745-6215-12-252.


Stable fluorophosphines: predicted and realized ligands for catalysis.

Fey N, Garland M, Hopewell JP, McMullin CL, Mastroianni S, Orpen AG, Pringle PG.

Angew Chem Int Ed Engl. 2012 Jan 2;51(1):118-22. doi: 10.1002/anie.201105954. Epub 2011 Nov 11. No abstract available.


Nanoporous organic alloys.

Natarajan R, Magro G, Bridgland LN, Sirikulkajorn A, Narayanan S, Ryan LE, Haddow MF, Orpen AG, Charmant JP, Hudson AJ, Davis AP.

Angew Chem Int Ed Engl. 2011 Nov 25;50(48):11386-90. doi: 10.1002/anie.201105216. Epub 2011 Oct 4. No abstract available.


The oxidative conversion of the N,S-bridged complexes [{RhLL'(μ-X)}2] to [(RhLL')3)(μ-X)2]+ (X = mt or taz): a comparison with the oxidation of N,N-bridged analogues.

Blagg RJ, López-Gómez MJ, Charmant JP, Connelly NG, Cowell JJ, Haddow MF, Hamilton A, Orpen AG, Riis-Johannessen T, Saithong S.

Dalton Trans. 2011 Nov 21;40(43):11497-510. doi: 10.1039/c1dt10930h. Epub 2011 Sep 27.


Mechanochemistry: opportunities for new and cleaner synthesis.

James SL, Adams CJ, Bolm C, Braga D, Collier P, Friščić T, Grepioni F, Harris KD, Hyett G, Jones W, Krebs A, Mack J, Maini L, Orpen AG, Parkin IP, Shearouse WC, Steed JW, Waddell DC.

Chem Soc Rev. 2012 Jan 7;41(1):413-47. doi: 10.1039/c1cs15171a. Epub 2011 Sep 5.


The timing, extent, progression and regression of deep vein thrombosis in immobile stroke patients: observational data from the CLOTS multicenter randomized trials.

Dennis M, Mordi N, Graham C, Sandercock P; CLOTS trials collaboration.

J Thromb Haemost. 2011 Nov;9(11):2193-200. doi: 10.1111/j.1538-7836.2011.04486.x.


The co-ordination chemistry of tris(3,5-dimethylpyrazolyl)methane manganese carbonyl complexes: synthetic, electrochemical and DFT studies.

Hallett AJ, Baber RA, Orpen AG, Ward BD.

Dalton Trans. 2011 Sep 28;40(36):9276-83. doi: 10.1039/c1dt10828j. Epub 2011 Aug 11.


Diphosphanes derived from phobane and phosphatrioxa-adamantane: similarities, differences and anomalies.

Dodds DL, Floure J, Garland M, Haddow MF, Leonard TR, McMullin CL, Orpen AG, Pringle PG.

Dalton Trans. 2011 Jul 21;40(27):7137-46. doi: 10.1039/c1dt10335k. Epub 2011 Jun 6.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk